Cancer Science最新文献

{"title":"Prostate cancer cancer-associated fibroblasts with stable markers post-androgen deprivation therapy associated with tumor progression and castration resistant prostate cancer","authors":"Shen Pan,&nbsp;Rui Yin,&nbsp;Hehe Zhu,&nbsp;Siang Shen,&nbsp;Zhenhua Li,&nbsp;Bitian Liu","doi":"10.1111/cas.16267","DOIUrl":"10.1111/cas.16267","url":null,"abstract":"<p>The specificity and clinical relevance of cancer-associated fibroblasts (CAFs) in prostate cancer (PCa), as well as the effect of androgen deprivation therapy (ADT) on CAFs, remain to be fully elucidated. Using cell lineage diversity and weighted gene co-expression network analysis (WGCNA), we pinpointed a unique CAF signature exclusive to PCa. The specificity of this CAF signature was validated through single-cell RNA sequencing (scRNA-seq), cell line RNA sequencing, and immunohistochemistry. This signature associates CAFs with tumor progression, elevated Gleason scores, and the emergence of castration resistant prostate cancer (CRPC). Using scRNA-seq on collected samples, we demonstrated that the CAF-specific signature is not altered by ADT, maintaining its peak signal output. Identifying a PCa-specific CAF signature and observing signaling changes in CAFs after ADT lay essential groundwork for further PCa studies.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 9","pages":"2893-2907"},"PeriodicalIF":4.5,"publicationDate":"2024-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.16267","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141545410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hepatocyte transformation is induced by laminin γ2 monomer","authors":"Nobuaki Funahashi,&nbsp;Hikari Okada,&nbsp;Ryo Kaneko,&nbsp;Kouki Nio,&nbsp;Taro Yamashita,&nbsp;Naohiko Koshikawa","doi":"10.1111/cas.16265","DOIUrl":"10.1111/cas.16265","url":null,"abstract":"<p>Serum laminin-γ2 monomer (Lm-γ2m) is a potent predictive biomarker for hepatocellular carcinoma (HCC) onset in patients with hepatitis C infection who achieve a sustained virologic response with liver cirrhosis (LC) and for the onset of extrahepatic metastases in early-stage HCC. Although Lm-γ2m involvement in late-stage cancer progression has been well investigated, its precise roles in HCC onset remain to be systematically investigated. Therefore, we analyzed an HCC model, human hepatocytes and cholangiocytes, and surgically resected liver tissues from patients with HCC to understand the roles of Lm-γ2m in HCC onset. Ck-19- and EpCAM-positive hepatic progenitor cells (HPCs) in the liver of <i>pdgf-c</i> transgenic HCC mouse model with ductular reaction showed ectopic expression of Lm-γ2m. Forced expression of Lm-γ2m in hepatocytes adjacent to HPCs resulted in enhanced tumorigenicity, cell proliferation, and migration in immortalized hepatocytes, but not in cholangiocytes in vitro. Further, pharmacological inhibition of epidermal growth factor receptor (EGFR) and c-Jun activator JNK suppressed Lm-γ2m-induced hepatocyte transformation, suggesting the involvement of EGFR/c-Jun signaling in the transformation, leading to HCC development. Finally, immunohistochemical staining of HCC tissues revealed a high level of Lm-γ2 expression in the HPCs of the liver with ductular reaction in normal liver adjacent to HCC tissues. Overall, HPC-derived Lm-γ2m in normal liver with ductular reaction acts as a paracrine growth factor on surrounding hepatocytes and promotes their cellular transformation through the EGFR/c-Jun signaling pathway. Furthermore, this is the first report on Lm-γ2m expression detected in the normal liver with ductular reaction, a human precancerous lesion of HCC.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 9","pages":"2972-2984"},"PeriodicalIF":4.5,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.16265","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multilayered proteomics reveals that JAM-A promotes breast cancer progression via regulation of amino acid transporter LAT1","authors":"Kazufumi Magara,&nbsp;Akira Takasawa,&nbsp;Kumi Takasawa,&nbsp;Tomoyuki Aoyama,&nbsp;Misaki Ota,&nbsp;Daisuke Kyuno,&nbsp;Yusuke Ono,&nbsp;Taro Murakami,&nbsp;Soh Yamamoto,&nbsp;Yuna Nakamori,&nbsp;Naoya Nakahashi,&nbsp;Goro Kutomi,&nbsp;Ichiro Takemasa,&nbsp;Tadashi Hasegawa,&nbsp;Makoto Osanai","doi":"10.1111/cas.16259","DOIUrl":"10.1111/cas.16259","url":null,"abstract":"<p>Recent studies have shown that transmembrane-type tight junction proteins are upregulated in various cancers compared with their levels in normal tissues and are involved in cancer progression, suggesting that they are potential therapeutic targets. Here, we demonstrated the expression profile and a novel role of junctional adhesion molecule-A (JAM-A) in breast cancer. Immunohistochemistry of surgical specimens showed that JAM-A was highly expressed from carcinoma in situ lesions, as in other adenocarcinomas, with higher expression in invasive carcinomas. High expression of JAM-A contributed to malignant aspects such as lymph node metastasis and lymphatic involvement positivity. In breast cancer cells, JAM-A expression status affects malignant potentials including proliferation and migration. Multilayered proteomics revealed that JAM-A interacts with the amino acid transporter LAT1 in breast cancer cells. JAM-A regulates the expression of LAT1 and interacts with it on the whole cell membrane, leading to enhanced amino acid uptake to promote tumor growth. Double high expression of JAM-A and LAT1 predicts poor prognosis in patients with breast cancer. Of note, an antibody against an extracellular domain of JAM-A suppressed the proliferation of breast cancer cells. Our findings indicate the possibility of JAM-A-targeted therapy ideally combined with LAT1-targeted therapy as a new therapeutic strategy against breast cancer.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 9","pages":"3153-3168"},"PeriodicalIF":4.5,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.16259","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression","authors":"Naomi Onda,&nbsp;Shinji Nakamichi,&nbsp;Mariko Hirao,&nbsp;Kuniko Matsuda,&nbsp;Masaru Matsumoto,&nbsp;Akihiko Miyanaga,&nbsp;Rintaro Noro,&nbsp;Akihiko Gemma,&nbsp;Masahiro Seike","doi":"10.1111/cas.16199","DOIUrl":"10.1111/cas.16199","url":null,"abstract":"<p>Osimertinib induces a marked response in non–small-cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) gene mutations. However, acquired resistance to osimertinib remains an inevitable problem. In this study, we aimed to investigate osimertinib-resistant mechanisms and evaluate the combination therapy of afatinib and chemotherapy. We established osimertinib-resistant cell lines (PC-9-OR and H1975-OR) from EGFR-mutant lung adenocarcinoma cell lines PC-9 and H1975 by high exposure and stepwise method. Combination therapy of afatinib plus carboplatin (CBDCA) and pemetrexed (PEM) was effective in both parental and osimertinib-resistant cells. We found that expression of thrombospondin-1 (TSP-1) was upregulated in resistant cells using cDNA microarray analysis. We demonstrated that TSP-1 increases the expression of matrix metalloproteinases through integrin signaling and promotes tumor invasion in both PC-9-OR and H1975-OR, and that epithelial-to-mesenchymal transition (EMT) was involved in H1975-OR. Afatinib plus CBDCA and PEM reversed TSP-1-induced invasion ability and EMT changes in resistant cells. In PC-9-OR xenograft mouse models (five female Balb/c-Nude mice in each group), combination therapy strongly inhibited tumor growth compared with afatinib monotherapy (5 mg/kg, orally, five times per week) or CBDCA (75 mg/kg, intraperitoneally, one time per week) + PEM (100 mg/kg, intraperitoneally, one time per week) over a 28-day period. These results suggest that the combination of afatinib plus CBDCA and PEM, which effectively suppresses TSP-1 expression, may be a promising option in EGFR-mutated NSCLC patients after the acquisition of osimertinib resistance.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 8","pages":"2718-2728"},"PeriodicalIF":4.5,"publicationDate":"2024-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Myc upregulates Ggct, γ-glutamylcyclotransferase to promote development of p53-deficient osteosarcoma","authors":"Tomoya Ueno,&nbsp;Shohei Otani,&nbsp;Yuki Date,&nbsp;Yu Katsuma,&nbsp;Yuma Nagayoshi,&nbsp;Tomoko Ito,&nbsp;Hiromi Ii,&nbsp;Susumu Kageyama,&nbsp;Susumu Nakata,&nbsp;Kosei Ito","doi":"10.1111/cas.16255","DOIUrl":"10.1111/cas.16255","url":null,"abstract":"<p>Osteosarcoma (OS) in humans is characterized by alterations in the <i>TP53</i> gene. In mice, loss of p53 triggers OS development, for which c-Myc (Myc) oncogenicity is indispensable. However, little is known about which genes are targeted by Myc to promote tumorigenesis. Here, we examined the role of γ-glutamylcyclotransferase (Ggct) which is a component enzyme of the γ-glutamyl cycle essential for glutathione homeostasis, in human and mouse OS development. We found that <i>GGCT</i> is a poor prognostic factor for human OS, and that deletion of <i>Ggct</i> suppresses <i>p53</i>-deficient osteosarcomagenesis in mice. Myc upregulates Ggct directly by binding to the <i>Ggct</i> promoter, and deletion of a Myc binding site therein by genome editing attenuated the tumorigenic potential of <i>p53</i>-deficient OS cells. Taken together, these results show a rationale that GGCT is widely upregulated in cancer cells and solidify its suitability as a target for anticancer drugs.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 9","pages":"2961-2971"},"PeriodicalIF":4.5,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.16255","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141460115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acquired copy number amplification at the MYC enhancer in human B-precursor acute lymphoblastic leukemia cell lines","authors":"Atsushi Watanabe,&nbsp;Lu Wang,&nbsp;Tze King Tan,&nbsp;Kevin Y. Urayama,&nbsp;Toshihiko Kizuki,&nbsp;Chiaki Komatsu,&nbsp;Keiko Kagami,&nbsp;Tamao Shinohara,&nbsp;Shin Kasai,&nbsp;Minori Tamai,&nbsp;Daisuke Harama,&nbsp;Koshi Akahane,&nbsp;Kumiko Goi,&nbsp;Hiroaki Goto,&nbsp;Kazuhito Satou,&nbsp;Tadashi Kaname,&nbsp;Takaomi Sanda,&nbsp;Takeshi Inukai","doi":"10.1111/cas.16260","DOIUrl":"10.1111/cas.16260","url":null,"abstract":"<p>Our study highlights the discovery of recurrent copy number alterations in noncoding regions, specifically blood enhancer cluster (<i>BENC-CNA</i>), in B-precursor acute lymphoblastic leukemia (BCP-ALL) cell lines. We demonstrate that <i>BENC-CNA</i> acts as a super-enhancer, driving <i>MYC</i> expression and possibly contributing to the immortalization and proliferative advantage of BCP-ALL cells in vitro.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 9","pages":"3196-3199"},"PeriodicalIF":4.5,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.16260","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141460113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RECK/GPR124-driven WNT signaling in pancreatic and gastric cancer cells","authors":"Hai Yu,&nbsp;Susumu Kohno,&nbsp;Dominic Chih-Cheng Voon,&nbsp;Nada Hamdy Hussein,&nbsp;Yuanyuan Zhang,&nbsp;Joji Nakayama,&nbsp;Yujiro Takegami,&nbsp;Chiaki Takahashi","doi":"10.1111/cas.16258","DOIUrl":"10.1111/cas.16258","url":null,"abstract":"<p>RECK has been described to modulate extracellular matrix components through negative regulation of MMP activities. Recently, RECK was demonstrated to bind to an orphan G protein-coupled receptor GPR124 to mediate WNT7 signaling in nontumor contexts. Here, we attempted to clarify the role of RECK in driving WNT signaling in cancer cells. RECK and GPR124 formed a complex in 293T cells, and when both were expressed, WNT signaling was significantly enhanced in a WNT7-dependent manner. This cooperation was abolished when RECK mutants unable to bind to GPR124 were transduced. RECK stimulated the growth of KRAS-mutated pancreatic ductal adenocarcinoma (PDAC) cells with increased sensitivity to WNT inhibitor in a GPR124-dependent manner. A gastric cancer cell line SH10TC endogenously expresses both RECK and GPR124 under regular culture conditions. In this cell line, inhibited cell growth and WNT signaling as well as increased apoptosis in the GPR124 depletion was dominantly found over those in the RECK deletion. These findings suggest that RECK promotes tumor cell growth by positively modulating WNT signaling through GPR124. This study proposes that the RECK/GPR124 complex might be a good therapeutic target in PDAC and gastric cancer.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 9","pages":"3013-3025"},"PeriodicalIF":4.5,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.16258","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141460182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes in non-small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first-line epidermal growth factor receptor tyrosine kinase inhibitors: A large real-world cohort study","authors":"Youyou Shao,&nbsp;Jingying Zhang,&nbsp;Zhi Feng,&nbsp;Wei Wu,&nbsp;Xiaotian Zhao,&nbsp;Minyi Zhu,&nbsp;Yao Xiao,&nbsp;Jiaohui Pang,&nbsp;Junfei Zhu,&nbsp;Hao Qu,&nbsp;Minchi Yuan,&nbsp;Guojie Xia,&nbsp;Meng Liu,&nbsp;Hengyuan Li","doi":"10.1111/cas.16250","DOIUrl":"10.1111/cas.16250","url":null,"abstract":"<p>Atypical L858R or other L858X mutations in the epidermal growth factor receptor (EGFR) gene, beyond the classical <i>EGFR</i>^L858R mutation caused by c.2573 T &gt; G, have been identified in non-small cell lung cancer (NSCLC), yet their genomic features and survival benefits with EGFR tyrosine kinase inhibitor (TKI) treatment have not been fully explored. We retrospectively enrolled 489 NSCLC patients with baseline tumor tissue/plasma samples carrying uncommon <i>EGFR</i>^L858R (<i>N</i> = 124), <i>EGFR</i>^L858Q/M (<i>N</i> = 17), or classical <i>EGFR</i>^L858R mutations (<i>N</i> = 348). The comparison of molecular features was performed using treatment-naïve tumor tissues. Survival benefits and resistance mechanisms of first-line EGFR TKI treatment were studied in an advanced disease subcohort. NSCLCs harboring uncommon <i>EGFR</i>^L858R had lower <i>TP53</i> mutation prevalence (<i>p</i> = 0.04) and chromosome instability scores (<i>p</i> = 0.02) than those with classical <i>EGFR</i>^L858R. Concomitant <i>EGFR</i>^L861Q mutations were enriched in NSCLCs with <i>EGFR</i>^L858Q/M (<i>p</i> &lt; 0.01), with cooccurrence in those carrying <i>EGFR</i>^L858M. Patients with uncommon <i>EGFR</i>^L858R experienced improved progression-free survival (PFS) compared to those with classical <i>EGFR</i>^L858R (median: 13.0 vs. 10.0 months, hazard ratio [HR]: 0.57, 95% confidence interval [CI]: 0.41–0.80). The association remained significant when adjusting for sex, age, histological subtype, TKI category, and anti-vascular therapy (HR: 0.55, 95% CI: 0.39–0.77). Furthermore, <i>EGFR</i>^L858Q/M patients showed enhanced first-line PFS (vs. classical <i>EGFR</i>^L858R, HR: 0.26, 95% CI: 0.10–0.67), potentially benefiting more from afatinib. Additionally, NSCLCs with uncommon <i>EGFR</i>^L858R and classical <i>EGFR</i>^L858R had similar resistance profiles to EGFR TKIs. In conclusion, NSCLCs carrying atypical <i>EGFR</i> L858 aberrations, which had fewer <i>TP53</i> mutations and higher chromosome stability, exhibited improved PFS under first-line EGFR TKIs than those with the classical <i>EGFR</i>^L858R.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 8","pages":"2751-2761"},"PeriodicalIF":4.5,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141460116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FoxG1/BNIP3 axis promotes mitophagy and blunts cisplatin resistance in osteosarcoma","authors":"Baolong Pan,&nbsp;Yan Li,&nbsp;Huiyun Han,&nbsp;Lu Zhang,&nbsp;Xuemei Hu,&nbsp;Yanyu Pan,&nbsp;Zhuohui Peng","doi":"10.1111/cas.16242","DOIUrl":"10.1111/cas.16242","url":null,"abstract":"<p>Cisplatin (CDDP) is a commonly used chemotherapeutic for osteosarcoma (OS) patients, and drug resistance remains as a major hurdle to undermine the treatment outcome. Here, we investigated the potential involvement of FoxG1 and BNIP3 in CDDP resistance of OS cells. FoxG1 and BNIP3 expression levels were detected in the CDDP-sensitive and CDDP-resistant OS tumors and cell lines. Mitophagy was observed through transmission electron microscope analysis. The sensitivity to CDDP in OS cells upon FoxG1 overexpression was examined in cell and animal models. We found that FoxG1 and BNIP3 showed significant downregulation in the CDDP-resistant OS tumor samples and cell lines. CDDP-resistant OS tumor specimens and cells displayed impaired mitophagy. FoxG1 overexpression promoted BNIP3 expression, enhanced mitophagy in CDDP-resistant OS cells, and resensitized the resistant cells to CDDP treatment in vitro and in vivo. Our data highlighted the role of the FoxG1/BNIP3 axis in regulating mitophagy and dictating CDDP resistance in OS cells, suggesting targeting FoxG1/BNIP3-dependent mitophagy as a potential strategy to overcome CDDP resistance in OS.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 8","pages":"2565-2577"},"PeriodicalIF":4.5,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141460114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impacts of cytoplasmic p53 aggregates on the prognosis and the transcriptome in lung squamous cell carcinoma","authors":"Kazuchika Nishitsuji,&nbsp;Remi Mito,&nbsp;Midori Ikezaki,&nbsp;Hiromu Yano,&nbsp;Yukio Fujiwara,&nbsp;Eri Matsubara,&nbsp;Taro Nishikawa,&nbsp;Yoshito Ihara,&nbsp;Kenji Uchimura,&nbsp;Naoyuki Iwahashi,&nbsp;Takuro Sakagami,&nbsp;Makoto Suzuki,&nbsp;Yoshihiro Komohara","doi":"10.1111/cas.16252","DOIUrl":"10.1111/cas.16252","url":null,"abstract":"<p>The tumor suppressor <i>TP53</i> gene, the most frequently mutated gene in human cancers, produces the product tumor protein p53, which plays an essential role in DNA damage. p53 protein mutations may contribute to tumorigenesis by loss of tumor suppressive functions and malignancy of cancer cells via gain-of-oncogenic functions. We previously reported that mutant p53 proteins form aggregates and that cytoplasmic p53 aggregates were associated with poor prognosis in human ovarian cancer. However, the prognostic impact of p53 aggregation in other tumors including lung squamous cell carcinoma (SCC) is poorly understood. Here, we demonstrated that lung SCC cases with cytoplasmic p53 aggregates had a significantly poor clinical prognosis. Analysis via patient-derived tumor organoids (PDOs) established from lung SCC patients and possessing cytoplasmic p53 aggregates showed that eliminating cytoplasmic p53 aggregates suppressed cell proliferation. RNA sequencing and transcriptome analysis of p53 aggregate-harboring PDOs indicated multiple candidate pathways involved in p53 aggregate oncogenic functions. With lung SCC-derived cell lines, we found that cytoplasmic p53 aggregates contributed to cisplatin resistance. This study thus shows that p53 aggregates are a predictor of poor prognosis in lung SCC and suggests that detecting p53 aggregates via p53 conventional immunohistochemical analysis may aid patient selection for platinum-based therapy.</p>","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"115 9","pages":"2947-2960"},"PeriodicalIF":4.5,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.16252","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141552895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}